New results support the practice of using antibodies to treat Alzheimer’s disease. The nine-month tests show better outcomes in cognitive performance and daily functioning in patients treated with IGIV compared to placebo treated patients. IGIV is an intravenous immunoglobulin called Gammagard. ... Click Here to Read More Click Here to Read More